China’s New Drug Procurement Program Shakes Up Big Pharma
The new bidding system for generic drugs upends the business of global drug makers in China. The big winners have been Chinese drug makers.
As part of its ambitious plan to reform the country’s healthcare system and lower drug costs, China has begun rolling out a centralized drug procurement system. The system rewards the cheapest price tag, with drug makers competing for contracts to supply generic drugs to the nation’s public hospitals and the government choosing the winners.
Two years into the program, it’s already clear who the losers are: global drug makers like Pfizer, Merck and Eli Lilly. The vast majority of contrac
Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
A weekly curated reading list on China from David Barboza, Pulitzer Prize-winning former Shanghai correspondent for The New York Times.
A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our Subscriptions page for details.
What is so hard about making chips in America? And can the U.S. do anything about it? As part of his series, 'Remaking the Chain,' Luke Patey went searching for answers from America's past and from the last country to threaten its mantle as the world’s leading economy.
The political scientist and sinologist talks about the early days of the pandemic in Wuhan, and how the Chinese authorities’ lack of transparency led the virus to spread rapidly.
A podcast about how the two nations, once friends, are now foes.
Hear why things are so complicated now. Host Jane Perlez, former New York Times Beijing bureau chief, talks with diplomats, spies, cultural superstars like Yo Yo Ma, and more to understand why the dangers are so high, and why relations went awry.